Tumorigenicity risk of iPSCs in vivo: nip it in the bud

26Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In 2006, Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4, Sox2, Klf44, and c-Myc. Since then, the future clinical application of somatic cell reprogramming technology has become an attractive research topic in the field of regenerative medicine. Of note, considerable interest has been placed in circumventing ethical issues linked to embryonic stem cell research. However, tumorigenicity, immunogenicity, and heterogeneity may hamper attempts to deploy this technology therapeutically. This review highlights the progress aimed at reducing induced pluripotent stem cells tumorigenicity risk and how to assess the safety of induced pluripotent stem cells cell therapy products.

Cite

CITATION STYLE

APA

Zhong, C., Liu, M., Pan, X., & Zhu, H. (2022). Tumorigenicity risk of iPSCs in vivo: nip it in the bud. Precision Clinical Medicine, 5(1). https://doi.org/10.1093/pcmedi/pbac004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free